William E Isaacs

US Patent:

7008765, Mar 7, 2006

Filed:

Apr 9, 1998

Appl. No.:

09/402713

Inventors:

Marion J. G. Bussemakers - Nijmegen, NL
William B. Isaacs - Glyndon MD, US

Assignee:

The Johns Hopkins University - Baltimore MD
Stichting Katholieke Universiteit more particularly The University Medical Centre - Nijmegen

International Classification:

C12Q 1/68
C07H 21/04
C12N 15/11
C12N 15/63

US Classification:

435 6, 536 231, 536 234, 536 2431, 4353201

Abstract:

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

US Patent:

7632643, Dec 15, 2009

Filed:

Oct 28, 2005

Appl. No.:

11/260282

Inventors:

Marion J. G. Bussemakers - Nijmegen, NL
William B. Isaacs - Glyndon MD, US

Assignee:

Stichting Katholieke Universiteit, More Particularly the University Medical Centre Nijmegen - Nijmegen
The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

US Patent:

8551699, Oct 8, 2013

Filed:

Oct 30, 2009

Appl. No.:

12/609483

Inventors:

Marion J. G. Bussemakers - Nijmegen, NL
William B. Isaacs - Glyndon MD, US

Assignee:

Stichting Katholieke Universiteit, more particularly The University of Medical Centre Nijmegen - Nijmegen
The Johns Hopkins University - Baltimore MD

International Classification:

C12Q 1/68

US Classification:

435 61, 435 611, 435 612, 435 614

Abstract:

The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.

US Patent:

20110110926, May 12, 2011

Filed:

Apr 16, 2009

Appl. No.:

12/988299

Inventors:

Jun Luo - Clarksville MD, US
George Steven Bova - Baltimore MD, US
William Isaacs - Glyndon MD, US
Thomas Dunn - Baltimore MD, US
Rong Hu - Catonsville MD, US

Assignee:

Johns Hopkins University - Baltimore MD

International Classification:

A61K 39/395
C07K 16/18
C07K 14/00
C07H 21/00
C07H 21/02
C12N 5/10
C40B 40/06
C12Q 1/68
G01N 33/53
C40B 30/04
A61K 31/7088
A61K 31/7105
A61K 31/713
A61P 35/00

US Classification:

4241301, 5303897, 530324, 536 235, 536 231, 4353201, 435325, 536 245, 506 16, 435 6, 435 721, 435 71, 506 9, 514 44 A, 514 44 R

Abstract:

The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.

US Patent:

55522777, Sep 3, 1996

Filed:

Jul 19, 1994

Appl. No.:

8/277202

Inventors:

William G. Nelson - Ruxton MD
William B. Isaacs - Glyndon MD
Wen-Hsiang Lee - Scottsdale AZ

Assignee:

The Johns Hopkins University School of Medicine - Baltimore MD

International Classification:

C07H 2102
C07H 2104
C12Q 168

US Classification:

435 6

Abstract:

A method for detecting and a method for treating a cell proliferative disorder associated with glutathione-S-transferase (GSTP1) expression is provided. The method includes direct detection of a hypermethylated GSTP1 promoter, or indirect detection of decreased GSTP1 mRNA or GSTP1 protein in a suspect tissue sample.

US Patent:

20230130223, Apr 27, 2023

Filed:

Dec 16, 2022

Appl. No.:

18/083221

Inventors:

- Baltimore MD, US
Christian P. Pavlovich - Baltimore MD, US
William Brewster Isaacs - Reisterstown MD, US
Jillian N. Eskra - Baltimore MD, US

International Classification:

C12Q 1/6886

Abstract:

Disclosed herein are methods for a RNA in situ hybridization assay workflow for the detection of target RNA within intact cells for the detection of prostate cancer cells in urine samples. The methods disclosed herein can identify a genetic susceptibility to prostate cancer in a subject and differentiate high risk from low risk prostate cancers. The methods disclosed herein can also include treatment and management strategies for prostate cancer and the prevention thereof.

US Patent:

20210108273, Apr 15, 2021

Filed:

Dec 10, 2020

Appl. No.:

17/117435

Inventors:

- Baltimore MD, US
George Steven Bova - Baltimore MD, US
William Isaacs - Glyndon MD, US
Thomas Dunn - Baltimore MD, US
Rong Hu - Catonsville MD, US

International Classification:

C12Q 1/6886
C07K 16/28

Abstract:

The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.

US Patent:

20210002729, Jan 7, 2021

Filed:

Mar 1, 2019

Appl. No.:

16/977281

Inventors:

- Baltimore MD, US
Christian P. Pavlovich - Baltimore MD, US
William Brewster Isaacs - Reisterstown MD, US
Jillian N. Eskra - Baltimore MD, US

International Classification:

C12Q 1/6886

Abstract:

Disclosed herein are methods for a RNA in situ hybridization assay workflow for the detection of target RNA within intact cells for the detection of prostate cancer cells in urine samples. The methods disclosed herein can identify a genetic susceptibility to prostate cancer in a subject and differentiate high risk from low risk prostate cancers. The methods disclosed herein can also include treatment and management strategies for prostate cancer and the prevention thereof.